---
title: "Buy Rating Backed by Strong Q4 Execution, FCF Inflection, and Undemanding Valuation Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277232324.md"
description: "OrthoPediatrics received a Buy rating from analyst Mathew Blackman of TD Cowen, with a price target of $23.00. The rating is supported by strong Q4 performance, positive free cash flow, and a reaffirmed 2026 outlook. Revenue exceeded expectations, and management's guidance is seen as achievable. Needham also maintains a Buy rating with a $30.00 price target, highlighting the stock's attractive upside potential due to its undemanding valuation and improving cash flow profile."
datetime: "2026-02-27T17:15:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277232324.md)
  - [en](https://longbridge.com/en/news/277232324.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277232324.md)
---

# Buy Rating Backed by Strong Q4 Execution, FCF Inflection, and Undemanding Valuation Upside

OrthoPediatrics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mathew Blackman from TD Cowen maintained a Buy rating on the stock and has a $23.00 price target.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Mathew Blackman has given his Buy rating due to a combination of factors including the company’s solid fourth-quarter performance and an encouraging free cash flow inflection. He notes that revenue came in slightly better than what was initially signaled and ahead of market expectations, while free cash flow turned positive and exceeded the earlier pre-announced range, indicating meaningful improvement in cash utilization.

He also emphasizes that management reaffirmed its 2026 outlook, which he views as achievable and potentially conservative given ongoing strength in core product lines and upcoming launches. Coupled with what he sees as an undemanding valuation and the transition to a free cash flow neutral or positive profile, he concludes that the shares have attractive upside potential relative to current levels.

In another report released today, Needham also maintained a Buy rating on the stock with a $30.00 price target.

### Related Stocks

- [KIDS.US](https://longbridge.com/en/quote/KIDS.US.md)

## Related News & Research

- [XTI Aerospace Reports Fourth Quarter and Full Year 2025 Results | UMAC Stock News](https://longbridge.com/en/news/282848031.md)
- [Bernstein Sticks to Their Buy Rating for 74SOFTWARE (0P5L)](https://longbridge.com/en/news/282689241.md)
- [Starco Brands Reports Fourth Quarter and Full Year 2025 Financial Results | STCB Stock News](https://longbridge.com/en/news/282750407.md)
- [Goldman Sachs Sticks to Its Buy Rating for Sensata (ST)](https://longbridge.com/en/news/282686538.md)
- [Smith-Midland Reports Fourth Quarter and Year End 2025 Financial Results | SMID Stock News](https://longbridge.com/en/news/282741161.md)